腫瘍病理鑑別診断アトラス　脳腫瘍

出版社： 文光堂
著者：
発行日： 2017-06-01
分野： 臨床医学：基礎  >  臨床病理学
ISBN： 9784830622526
シリーズ： 腫瘍病理鑑別診断アトラス
電子書籍版： 2017-06-01 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

17,600 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

17,600 円(税込)

購入する

商品紹介

脳腫瘍の病理診断が難しい要因の一つとして，組織・免疫・遺伝学的所見が必ずしも腫瘍型に特異的ではないことが挙げられる．それを補うために，形態情報に加えて，臨床，画像，遺伝子情報を統合的に判断するintegrated diagnosisが提唱されている．臨床画像情報から候補となる腫瘍を思い浮かべつつHE標本を鏡検し，必要な免疫組織化学染色と遺伝学的検査を選択する診断の流れを学ぶ．

目次

  • 腫瘍病理鑑別診断アトラス　脳腫瘍

    ―目次―

    第１部　検鏡前の確認事項
    　I．脳腫瘍組織分類の現状
    　　１．WHO中枢神経系腫瘍分類改訂の概要
    　　２．びまん性星細胞系および乏突起膠細胞系腫瘍
    　　３．その他の星細胞系腫瘍
    　　４．上衣系腫瘍
    　　５．神経細胞性および混合神経細胞─膠細胞系腫瘍
    　　６．胎児性腫瘍
    　　７．神経鞘腫瘍
    　　８．髄膜腫
    　　９．間葉系腫瘍
    　　10．リンパ腫と組織球性腫瘍
    　II．脳腫瘍の画像診断
    　　１．知っておくべき放射線学的診断法
    　　２．診断に大きく影響を与える代表的な画像所見
    　III．病理検体の取扱い
    　　１．検体を扱う前に：病理診断依頼書で確認する事項
    　　２．術中迅速診断等の小検体の取扱い
    　　３．切除材料の取扱い
    　IV．脳腫瘍の分子遺伝学
    　　１．脳腫瘍における遺伝子異常の全体像
    　　２．遺伝子プロファイルに基づく治療戦略
    　　３．脳腫瘍におけるクリニカルシーケンスの実際

    第２部　組織型と診断の実際
    　I．浸潤性星細胞腫と乏突起膠腫
    　　１．IDH変異型・浸潤性星細胞腫
    　　２．IDH野生型・膠芽腫
    　　３．膠芽腫の亜型
    　　４．IDH変異・1p/19q共欠失乏突起膠腫
    　　５．小児の浸潤性神経膠腫
    　II．その他の星細胞腫と上衣細胞系腫瘍
    　　１．限局性星細胞腫
    　　２．上衣系腫瘍，脈絡叢腫瘍
    　III．神経細胞系腫瘍と胎児性腫瘍
    　　１．神経細胞系腫瘍
    　　２．松果体部腫瘍
    　　３．胎児性腫瘍
    　IV．間葉系腫瘍
    　　１．髄膜腫
    　　２．末梢神経腫瘍
    　　３．その他の間葉系腫瘍
    　V．その他の腫瘍
    　　１．血液系腫瘍
    　　２．胚細胞性腫瘍

    第３部　鑑別ポイント
    　I．術中迅速診断・細胞診
    　　１．術中迅速診断の留意点
    　　２．術中迅速診断の目的
    　　３．凍結組織標本で注意すべき人工産物（アーチファクト）
    　　４．迅速診断のポイント
    　II．免疫組織化学の実際
    　III．腫瘍と鑑別を要する非腫瘍性病変
    　　１．非特異的反応性変化
    　　２．放射線治療後の変化─偽増悪と遅発性放射線壊死─
    　　３．感染症
    　　４．炎症性脱髄性疾患
    　　５．血管炎
    　　６．脳血管障害

    第４部　臨床との連携
    　I．脳腫瘍の臨床診断と病理情報
    　　　　―脳神経外科医から病理診断医への9つのメッセージ―
    　　１．病理診断を待っています
    　　２．頭部MR入門
    　　３．迅速診断での注意1─BCNU wafer留置─
    　　４．迅速診断での注意2─必要要件を満たした返事で十分─
    　　５．迅速診断での注意3─定位生検・内視鏡診断─
    　　６．転移性脳腫瘍─re-biopsy部位としての脳実質
    　　７．成人大脳半球初発膠芽腫の治療
    　　８．高齢者の膠芽腫治療
    　　９．中枢神経系悪性リンパ腫
    　II．組織学的治療効果判定
    　III．病理診断報告書の記載法

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1部 検鏡前の確認事項

P.13 掲載の参考文献
1) Louis DN, Ohgaki H, Wiestler OD et al (eds) : WHO Classification of Tumours of the Central Nervous System, 4th ed revised, IARC Press, Lyon, 2016
 
2) Yan H, Parsons DW, Jin G et al : IDH1 and IDH2 mutations in gliomas. N Engl J Med 360 : 765-773, 2009
PubMed
3) Reifenberger J, Reifenberger G, Liu L et al : Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145 : 1175-1190, 1994
PubMed
4) Sahm F, Reuss D, Koelsche C et al : Farewell to oligoastrocytoma : in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol 128 : 551-559, 2014
PubMed
5) Louis DN, Perry A, Burger P et al : International Society of Neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 24 : 429-435, 2014
PubMed
6) Louis DN, Perry A, Reifenberger G et al : The 2016 World Health Organization Classification of Tumors of the Central Nervous System : a summary. Acta Neuropathol 131 : 803-820, 2016
PubMed
7) Ohgaki H, Kleihues P : The definition of primary and secondary glioblastoma. Clin Cancer Res 19 : 764-772, 2013
 
8) Perry A, Miller CR, Gujrati M et al : Malignant gliomas with primitive neuroectodermal tumor-like components : a clinicopathologic and genetic study of 53 cases. Brain Pathol 19 : 81-90, 2009
 
9) Kleinschmidt-DeMasters BK, Aisner DL, Birks DK et al : Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol 37 : 685-698, 2013
PubMed
10) Lewis PW, Muller MM, Koletsky MS et al : Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 340 : 857-861, 2013
PubMed
11) Johnson MW, Eberhart CG, Perry A et al : Spectrum of pilomyxoid astrocytoma : intermediate pilomyxoid tumors. Am J Surg Pathol 34 : 1783-1791, 2010
PubMed
12) Giannini C, Scheithauer BW, Burger PC et al : Pleomorphic xanthoastrocytoma : what do we really know about it? Cancer 85 : 2033-2045, 1999
PubMed
13) Witt H, Mack SC, Ryzhova M et al : Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 20 : 143-157, 2011
PubMed
14) Pajtler KW, Witt H, Sill M et al : Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell 27 : 728-743, 2015
PubMed
15) Parker M, Mohankumar KM, Punchihewa C et al : C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma. Nature 506 : 451-455, 2014
 
16) Gardiman MP, Fassan M, Orvieto E et al : Diffuse leptomeningeal glioneuronal tumor : a new entity? Brain Pathol 20 : 361-366, 2010
PubMed
17) Huse JT, Edgar M, Halliday J et al : Multinodular and vacuolating neuronal tumors of the cerebrum : 10 cases of a distinctive seizure-associated lesion. Brain Pathol 23 : 515-524, 2013
PubMed
18) Taylor MD, Northcott PA, Korshunov A et al : Molecular subgroups of medulloblastoma : the current consensus. Acta Neuropathol 123 : 465-472, 2012
PubMed
19) Nobusawa S, Yokoo H, Hirato J et al : Analysis of chromosome 19q13.42 amplification in embryonal brain tumors with ependymoblastic multilayered rosettes. Brain Pathol 22 : 689-697, 2012
PubMed
20) Korshunov A, Ryzhova M, Jones DTW et al : LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR). Acta Neuropathol 124 : 875-881, 2012
PubMed
21) Sturm D, Orr BA, Toprak UH et al : New brain tumor entities emerge from molecular classification of CNS-PNETs. Cell 164 : 1060-1072, 2016
PubMed
22) Perry A : WHO's arrived in 2016! An updated weather forecast for integrated brain tumor diagnosis. Brain Tumor Pathol 33 : 157-160, 2016
PubMed
23) Hornick JL, Bundock EA, Fletcher CD : Hybrid schwannoma/perineurioma : clinicopathologic analysis of 42 distinctive benign nerve sheath tumors. Am J Surg Pathol 33 : 1554-1561, 2009
PubMed
24) Schweizer L, Koelsche C, Sahm F et al : Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol 125 : 651-658, 2013
PubMed
P.23 掲載の参考文献
1) Aoyama H, Shirato H, Tago M et al : Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases : a randomized controlled trial. JAMA 295 : 2483-2491, 2006
PubMed
2) McMonagle B, Al-Sanosi A, Croxson G et al : Facial schwannoma : results of a large case series and review. J Laryngol Otol 122 : 1139-1150, 2008
PubMed
3) Kondziolka D, Nathoo N, Flickinger JC et al : Long-term results after radiosurgery for benign intracranial tumors. Neurosurgery 53 : 815-821, 2003
PubMed
4) Stadnik TW, Chaskis C, Michotte A et al : Dif fusionweighted MR imaging of intracerebral masses : comparison with conventional MR imaging and histologic findings. AJNR Am J Neuroradiol 22 : 969-976, 2001
 
5) 細矢貴亮, 鹿戸将史, 岡本浩一郎他 : 脳腫瘍. 細矢貴亮, 興梠征典, 三木幸雄他 (編) : 脳のMRI. メディカル・サイエンス・インターナショナル, 2015, pp55-242
 
6) Hakyemez B, Erdogan C, Ercan I et al : High-grade and low-grade gliomas : differentiation by using perfusion MR imaging. Clin Radiol 60 : 493-502, 2005
PubMed
7) Mittal S, Wu Z, Neelavalli J et al : Susceptibility-weighted imaging : technical aspects and clinical applications, part 2. AJNR Am J Neuroradiol 30 : 232-252, 2009
PubMed
8) M?ller-Hartmann W, Herminghaus S, Krings T et al : Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology 44 : 371-381, 2002
 
9) Jellison BJ, Field AS, Medow J et al : Diffusion tensor imaging of cerebral white matter : a pictorial review of physics, fiber tract anatomy, and tumor imaging patterns. AJNR Am J Neuroradiol 25 : 356-369, 2004
PubMed
10) Nimsky C, Ganslandt O, Hastreiter P et al : Preoperative and intraoperative diffusion tensor imaging-based fiber tracking in glioma surgery. Neurosurgery 61 (Suppl 1) : 178-185, 2007
 
11) Kinoshita M, Yamada K, Hashimoto N et al : Fiber-tracking does not accurately estimate size of fiber bundle in pathological condition : initial neurosurgical experience using neuronavigation and subcortical white matter stimulation. Neuroimage 25 : 424-429, 2005
 
12) Mueller WM, Yetkin FZ, Hammeke TA et al : Functional magnetic resonance imaging mapping of the motor cortex in patients with cerebral tumors. Neurosurgery 39 : 515-520, 1996
PubMed
13) Roux FE, Boulanouar K, Lotterie JA et al : Language functional magnetic resonance imaging in preoperative assessment of language areas : correlation with direct cortical stimulation. Neurosurgery 52 : 1335-1345, 2003
PubMed
14) Pearce MS, Salotti JA, Little MP et al : Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours : a retrospective cohort study. Lancet 380 : 499-505, 2012
PubMed
15) 日本脳神経外科学会, 日本病理学会 (編) : 臨床・病理 脳腫瘍取扱い規約, 第3版. 金原出版, 2010, pp172-216
 
16) Kaschten B, Stevenaert A, Sadzot B et al : Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 39 : 778-785, 1998
PubMed
17) Terakawa Y, Tsuyuguchi N, Iwai Y et al : Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med 49 : 694-699, 2008
PubMed
18) 青木茂樹, 相田典子, 井田正博 他 : よくわかる脳MRI, 第3版. 秀潤社, 2012, pp43-239
 
19) Modha A, Gutin PH : Diagnosis and treatment of atypical and anaplastic meningiomas : a review. Neurosurgery 57 : 538-550, 2005
PubMed
20) 日向野修一, 栗原紀子 : 脳腫瘍. 高橋昭喜 (編著) : 脳MRI 3. 血管障害・腫瘍・感染症・他. 秀潤社, 2010, pp206-420
 
P.29 掲載の参考文献
1) 横尾英明, 伊古田勇人 : 術中生検診断のポイント. 青笹克之, 中里洋一 (編) : 癌診療指針のための病理診断プラクティス-脳腫瘍. 中山書店, 2012, pp23-26
 
2) Raisanen J, White CL III : Central nervous system. in Taxy JB, Husain AN, Montag AG (eds) : "Biopsy Interpretation : The Frozen Section". Lippincott Williams & Wilkins, Philadelphia, 2014, pp378-413
 
3) Joseph JT : Diagnostic Neuropathology Smears. Lippincott Williams & Wilkins, Philadelphia, 2007, pp7-11
 
4) 鈴木博義 : 脳腫瘍病理検体の取り扱い. 青笹克之, 中里洋一 (編) : 癌診療指針のための病理診断プラクティス-脳腫瘍. 中山書店, 2012, pp292-300
 
5) 日本病理学会 : ゲノム研究用病理組織検体取扱い規程. 2016, pp29-67, 69-92
 
P.39 掲載の参考文献
1) Rasheed BK, Wiltshire RN, Bigner SH et al : Molecular pathogenesis of malignant gliomas. Curr Opin Oncol 11 : 162-167, 1999
PubMed
2) Cancer Genome Atlas Network : Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455 : 1061-1068, 2008
PubMed
3) Cancer Genome Atlas Research Network : Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17 : 98-110, 2010
 
4) Cancer Genome Atlas Research Network : Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17 : 510-522, 2010
 
5) Louis DN, Ohgaki H, Wiestler OD et al (eds) : WHO Classification of Tumours of the Central Nervous System. 4th ed revised, IARC Press, Lyon, 2016
 
6) Parsons DW, Jones S, Zhang X et al : An integrated genomic analysis of human glioblastoma multiforme. Science 321 : 1807-1012, 2008
 
7) Jones DT, Kocialkowski S, Liu L et al : Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 68 : 8673-8677, 2008
PubMed
8) St. Jude Children's Research Hospital Washington University Pediatric Cancer Genome Project : Whole-genome sequencing identifies genetic alterations in pediatric lowgrade gliomas. Nat Genet 45 : 602-612, 2013
 
9) Rouleau GA, Merel P, Lutchman M et al : Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363 : 515-521, 1993
 
10) Ruttledge MH, Sarrazin J, Rangaratnam S et al : Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet 6 : 180-184, 1994
PubMed
11) Clark VE, Erson-Omay EZ, Serin A et al : Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339 : 1077-1080, 2013
PubMed
12) Yuzawa S, Nishihara H, Yamaguchi S et al : Clinical impact of targeted amplicon sequencing for meningioma as a practical clinical-sequencing system. Mod Pathol 29 : 708-716, 2016
PubMed
13) Pajtler KW, Witt H, Sill M et al : Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. Cancer Cell 27 : 728-743, 2015
PubMed
14) Buczkowicz P, Hoeman C, Rakopoulos P et al : Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet 46 : 451-456, 2014
PubMed
15) Northcott PA, Jones DT, Kool M et al : Medulloblastomics : the end of the beginning. Nat Rev Cancer 12 : 818-834, 2012
PubMed
16) Nishihara H : Human pathological basis of blood vessels and stromal tissue for nanotechnology. Adv Drug Deliv Rev 74 : 19-27, 2014
 
17) 西原広史 : がん微小環境の性状に合わせた個別化治療の可能性. 宮園浩平 (監) : がん微小環境と標的治療. 実験医学 33 (増刊) : 192-198, 2015
 
18) 西原広史 : ホルマリン固定パラフィン包埋 (FFPE) 標本の作製・保管. 深山正久, 金井弥栄, 田中伸哉 (編) : 癌の分子病理学, 病理と臨床 34 (臨増) : 27-34, 2016
 
19) 西原広史 : ホルマリン固定パラフィン包埋標本の適切な作製・保管方法. 深山正久, 小田義直, 金井弥栄 (編) : ゲノム研究用病理組織検体取り扱い規程. 日本病理学会 2016, pp69-92
 
20) 西原広史, 赤羽俊章, 毛利普美 : FFPE検体を利用した次世代シークエンサーによるクリニカルシークエンス. 検査と技術 43 : 458-463, 2015
 
21) Lai RK, Chen Y, Guan X et al : Genome-wide methylation analyses in glioblastoma multiforme. PLoS One 9 : e89376, 2014
PubMed

第2部 組織型と診断の実際

P.53 掲載の参考文献
1) Louis DN, Perry A, Reifenberger G et al : The 2016 World Health Organization Classification of Tumors of the Central Nervous System : a summary. Acta Neuropathol 131 : 803-820, 2016
PubMed
2) von Deimling A, Huse JT, Yan H et al : Diffuse astrocytoma, IDH-mutant. in Louis DN, Ohgaki H, Wiestler OD et al (eds) : "WHO Classification of Tumours of the Central Nervous System", IARC Press, Lyon, 2016, pp18-23
 
3) Scherer HJ : A critical review : The pathology of cerebral gliomas. J Neurol Psychiatry 3 : 147-177, 1940
PubMed
4) Yan H, Parsons DW, Jin G et al : IDH1 and IDH2 mutations in gliomas. N Engl J Med 360 : 765-773, 2009
PubMed
5) Lu C, Ward PS, Kapoor GS et al : IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483 : 474-478, 2012
 
6) Turcan S, Rohle D, Goenka A et al : IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483 : 479-483, 2012
PubMed
7) The Cancer Genome Atlas Research Network : Comprehensive, integrative genomic analysis of diffuse lowergrade gliomas. N Engl J Med 372 : 2481-2498, 2015
 
8) Suzuki H, Aoki K, Chiba K et al : Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 47 : 458-468, 2015
PubMed
9) Heaphy CM, de Wilde RF, Jiao Y et al : Altered telomeres in tumors with ATRX and DAXX mutations. Science 333 : 425, 2011
PubMed
10) Takami H, Yoshida A, Fukushima S et al : Revisiting TP53 mutations and immunohistochemistry. A comparative study in 157 diffuse gliomas. Brain Pathol 25 : 256-265, 2015
PubMed
11) Reuss DE, Sahm F, Schrimpf D et al : ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 129 : 133-146, 2015
PubMed
12) Ikemura M, Shibahara J, Mukasa A et al : Utility of ATRX immunohistochemistry in diagnosis of adult diffuse gliomas. Histopathology 69 : 260-267, 2016
PubMed
13) McDonald JM, See SJ, Tremont IW et al : The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer 104 : 1468-1477, 2005
PubMed
14) 柴原純二 : 乏突起膠腫. 日本臨床 74 (Suppl 7) : 192-195, 2016
 
15) Eckel-Passow JE, Lachance DH, Molinaro AM et al : Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372 : 2499-2508, 2015
PubMed
16) Reuss DE, Kratz A, Sahm F et al : Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathol 130 : 407-417, 2015
PubMed
17) Labussiere M, Idbaih A, Wang XW et al : All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology 74 : 1886-1890, 2010
 
18) von Deimling A, Huse JT, Yan H et al : Anaplastic astrocytoma, IDH-mutant. in Louis DN, Ohgaki H, Wiestler OD, et al (eds) : "WHO Classification of Tumours of the Central Nervous System", IARC Press, Lyon, 2016, pp24-27
 
19) Reuss DE, Mamatjan Y, Schrimpf D et al : IDH mutant diffuse and anplastic astrocytomas have similar age at presentation and little difference in survival : a grading problem for WHO. Acta Neuropathol 129 : 867-873, 2015
 
20) Seiz M, Tuettenberg J, Meyer J et al : Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component : evidence for molecular subtypes. Acta Neuropathol 120 : 261-267, 2010
PubMed
21) Tabouret E, Nguyen AT, Dehais C et al : Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort. Acta Neuropathol 132 : 625-634, 2016
PubMed
22) Ohgaki H, Kleihues P, von Deimling A et al : Glioblastoma, IDH-mutant. in Louis DN, Ohgaki H, Wiestler OD, et al (eds) : "WHO Classification of Tumours of the Central Nervous System", IARC Press, Lyon, 2016, pp52-56
 
23) Nobusawa S, Watanabe T, Kleihues P et al : IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15 : 6002-6007, 2009
PubMed
24) Andronesi OC, Kim GS, Gerstner E et al : Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med 4 : 116ra4, 2012
PubMed
25) Lai A, Kharbanda S, Pope WB et al : Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 29 : 4482-4490, 2011
PubMed
26) Joseph NM, Phillips J, Dahiya S et al : Diagnostic implications of IDH1-R132H and OLIG2 expression patterns in rare and challenging glioblastoma variants. Mod Pathol 26 : 315-326, 2013
PubMed
27) Perry A, Aldape KD, George DH et al : Small cell astrocytoma : an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma. Cancer 101 : 2318-2326, 2004
PubMed
28) Chen L, Voronovich Z, Clark K et al : Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma. Neuro Oncol 16 : 1478-1483, 2014
PubMed
29) Verhaak RG, Hoadley KA, Purdom E et al : Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1 EGFR, and NF1. Cancer Cell 17 : 98-110, 2010
PubMed
30) Noushmehr H, Weisenberger DJ, Diefes K et al : Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17 : 510-522, 2010
PubMed
31) Louis DN, Aldape K, Brat DJ et al : cIMPCT-NOW (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy) : a new initiative in advancing ner vous system tumor classification. Brain Pathol (in press)
 
P.66 掲載の参考文献
1) Ostrom QT, Bauchet L, Davis FG et al : The epidemiology of glioma in adults : a "state of the science" review. Neuro Oncol 16 : 896-913, 2014
PubMed
2) Hinrichs BH, Newman S, Appin CL et al : Farewell to GBM-O : Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups. Acta Neuropathol Commun 4 : 4, 2016
PubMed
3) Capper D, Weissert S, Balss J et al : Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20 : 245-254, 2010
PubMed
4) Kato Y : Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas. Brain Tumor Pathol 32 : 3-11, 2015
PubMed
5) Chen L, Voronovich Z, Clark K et al : Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma. Neuro Oncol 16 : 1478-1483, 2014
PubMed
6) Esteller M, Garcia-Foncillas J, Andion E et al : Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343 : 1350-1354, 2000
PubMed
7) Reuss DE, Kratz A, Sahm F et al : Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathol 130 : 407-417, 2015
PubMed
8) Bechet D, Gielen GG, Korshunov A et al : Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas. Acta Neuropathol 128 : 733-741, 2014
PubMed
9) Korshunov A, Capper D, Reuss D et al : Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. Acta Neuropathol 131 : 137-146, 2016
PubMed
10) Takei H, Rouah E, Ishida Y : Brain metastasis : clinical characteristics, pathological findings and molecular subtyping for therapeutic implications. Brain Tumor Pathol 33 : 1-12, 2016
PubMed
11) Nonaka D, Chiriboga L, Rubin BP : Sox10 : a panschwannian and melanocytic marker. Am J Surg Pathol 32 : 1291-1298, 2008
 
12) Arita H, Yamasaki K, Matsushita Y et al : A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathol Commun 4 : 79, 2016
PubMed
P.74 掲載の参考文献
1) Louis DN, Ohgaki H, Wiestler OD et al (eds) : WHO Classification of Tumours of the Central Nervous System, 4th edition revised, IARC Press, Lyon, 2016
 
2) Louis DN, Perry A, Reifenberger G et al : The 2016 World Health Organization Classification of Tumors of the Central Nervous System : a summary. Acta Neuropathol 131 : 803-820, 2016
PubMed
3) Belsuzarri TA, Araujo JF, Catanoce AP et al : Giant cells glioblastoma : case report and pathological analysis from this uncommon subtype of glioma. Rare Tumors 7 : 5634, 2015
PubMed
4) Kozak KR, Moody JS : Giant cell glioblastoma : a glioblastoma subtype with distinct epidemiology and superior prognosis. Neuro Oncol 11 : 833-841, 2009
PubMed
5) Oh JE, Ohta T, Nonoguchi N et al : Genetic alterations in gliosarcoma and giant cell glioblastoma. Brain Pathol 26 : 517-522, 2016
PubMed
6) Singh G, Das KK, Sharma P et al : Cerebral gliosarcoma : Analysis of 16 patients and review of literature. Asian J Neurosurg 10 : 195-202, 2015
PubMed
7) Cachia D, Kamiya-Matsuoka C, Mandel JJ et al : Primary and secondary gliosarcomas : clinical, molecular and survival characteristics. J Neurooncol 125 : 401-410, 2015
PubMed
8) Sugimoto K, Ideguchi M, Kimura T et al : Epithelioid/rhabdoid glioblastoma : a highly aggressive subtype of glioblastoma. Brain Tumor Pathol 33 : 137-146, 2016
PubMed
9) Behling F, Barrantes-Freer A, Skardelly M et al : Frequency of BRAF V600E mutations in 969 central nervous system neoplasms. Diagn Pathol 11 : 55, 2016
 
10) Kanamori M, Suzuki H, Takei H et al : Malignant transformation of diffuse astrocytoma to glioblastoma associated with newly developed BRAF V600E mutation. Brain Tumor Pathol 33 : 50-56, 2016
PubMed
11) Kuroda J, Nobusawa S, Nakamura H et al : A case of an epithelioid glioblastoma with the BRAF V600E mutation colocalized with BRAF intact low-grade diffuse astrocytoma. Neuropathology 36 : 181-186, 2016
PubMed
12) Matsumura N, Nakajima N, Yamazaki T et al : Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low-grade astrocytoma. Neuropathology 37 : 58-63, 2017
PubMed
P.82 掲載の参考文献
1) Louis DN, Ohgaki H, Wiestler OD et al (eds) : WHO Classification of Tumours of the Central Nervous System, 4th ed revised. IARC Press, Lyon, 2016
 
2) Louis DN, Perry A, Burger P et al : International Society Of Neuropathology -Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 24 : 429-435, 2014
PubMed
3) Sahm F, Reuss D, Koelsche C et al : Farewell to oligoastrocytoma : in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol 128 : 551-559, 2014
PubMed
4) Capper D, Zentgraf H, Balss J et al : Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 118 : 599-601, 2009
PubMed
5) Reuss DE, Sahm F, Schrimpf D et al : ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 129 : 133-146, 2015
PubMed
6) Ikemura M, Shibahara J, Mukasa A et al : Utility of ATRX immunohistochemistry in diagnosis of adult diffuse gliomas. Histopathology 69 : 260-267, 2016
PubMed
7) Suzuki A, Nobusawa S, Natsume A et al : Olig2 labeling index is correlated with histological and molecular classifications in low-grade diffuse gliomas. J Neurooncol 120 : 283-291, 2014
PubMed
8) Arai H, Ikota H, Sugawara K et al : Nestin expression in brain tumors : its utility for pathological diagnosis and correlation with the prognosis of high-grade gliomas. Brain Tumor Pathol 29 : 160-167, 2012
PubMed
9) Perry A, Burton SS, Fuller GN et al : Oligodendroglial neoplasms with ganglioglioma-like maturation : a diagnostic pitfall. Acta Neuropathol 120 : 237-252, 2010
PubMed
10) Qu M, Olofsson T, Sigurdardottir S et al : Genitically distinct astrocytic and oligodendroglial components in oligoastrocytomas. Acta Neuropathol 113 : 129-136, 2007
 
P.91 掲載の参考文献
1) Louis DN, Perry A, Reifenberger G et al : The 2016 World Health Organization Classification of Tumors of the Central Nervous System : a summary. Acta Neuropathol 131 : 803-820, 2016
PubMed
2) Parsons DW, Jones S, Zhang X et al : An integrated genomic analysis of human glioblastoma multiforme. Science 321 : 1807-1812, 2008
 
3) Schwartzentruber J, Korshunov A, Liu XY et al : Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482 : 226-231, 2012
PubMed
4) Masui K, Mischel PS, Reifenberger G : Molecular classification of gliomas. Handb Clin Neurol 134 : 97-120, 2016
PubMed
5) Louis DN, Perry A, Burger P et al : International Society Of Neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 24 : 429-435, 2014
PubMed
6) Reuss DE, Sahm F, Schrimpf D et al : ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 129 : 133-146, 2015
PubMed
7) Brat DJ, Verhaak RG, Aldape KD et al : Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372 : 2481-2498, 2015
PubMed
8) Suzuki H, Aoki K, Chiba K et al : Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 47 : 458-468, 2015
PubMed
9) Zhang J, Wu G, Miller CP et al : Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 45 : 602-612, 2013
 
10) Collins VP, Jones DT, Giannini C : Pilocytic astrocytoma : pathology, molecular mechanisms and markers. Acta Neuropathol 129 : 775-788, 2015
PubMed
11) Castel D, Philippe C, Calmon R et al : Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol 130 : 815-827, 2015
PubMed
12) Sturm D, Witt H, Hovestadt V et al : Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22 : 425-437, 2012
PubMed
13) Rodriguez FJ, Tihan T, Lin D et al : Clinicopathologic features of pediatric oligodendrogliomas : a series of 50 patients. Am J Surg Pathol 38 : 1058-1070, 2014
PubMed
14) Bechet D, Gielen GG, Korshunov A et al : Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas. Acta Neuropathol 128 : 733-741, 2014
PubMed
P.99 掲載の参考文献
1) Louis DN, Ohgaki H, Wiestler OD et al (eds) : WHO Classification of Tumours of the Central Nervous System. 4th ed revised. IARC Press, Lyon, 2016
 
2) Tomlinson FH, Scheithauer BW, Hayostek CJ et al : The significance of atypia and histologic malignancy in pilocytic astrocytoma of the cerebellum : a clinicopathologic and flow cytometric study. J Child Neurol 9 : 301-310, 1994
PubMed
3) Rodriguez FJ, Scheithauer BW, Burger PC et al : Anaplasia in pilocytic astrocytoma predicts aggressive behavior. Am J Surg Pathol 34 : 147-160, 2010
PubMed
4) Jones DT, Kocialkowski S, Liu L et al : Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 68 : 8673-8677, 2008
PubMed
5) Collins VP, Jones DT, Giannini C : Pilocytic astrocytoma : pathology, molecular mechanisms and markers. Acta Neuropathol 129 : 775-788, 2015
PubMed
6) Schindler G, Capper D, Meyer J et al : Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121 : 397-405, 2011
PubMed
7) Jones DT, Hutter B, Jager N et al : Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet 45 : 927-932, 2013
PubMed
8) Colin C, Padovani L, Chappe C et al : Outcome analysis of childhood pilocytic astrocytomas : a retrospective study of 148 cases at a single institution. Neuropathol Appl Neurobiol 39 : 693-705, 2013
 
9) Becker AP, Scapulatempo-Neto C, Carloni AC et al : KIAA1549 : BRAF Gene Fusion and FGFR1 Hotspot Mutations Are Prognostic Factors in Pilocytic Astrocytomas. J Neuropathol Exp Neurol 74 : 743-754, 2015
PubMed
10) Korshunov A, Meyer J, Capper D et al : Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol 118 : 401-405, 2009
PubMed
11) Zhang J, Wu G, Miller CP et al : Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 45 : 602-612, 2013
 
12) Brat DJ, Scheithauer BW, Fuller GN et al : Newly codified glial neoplasms of the 2007 WHO Classification of Tumours of the Central Nervous System : angiocentric glioma, pilomyxoid astrocytoma and pituicytoma. Brain Pathol 17 : 319-324, 2007
PubMed
13) Chikai K, Ohnishi A, Kato T et al : Clinico-pathological features of pilomyxoid astrocytoma of the optic pathway. Acta Neuropathol 108 : 109-114, 2004
PubMed
14) Tihan T, Fisher PG, Kepner JL et al : Pediatric astrocytomas with monomorphous pilomyxoid features and a less favorable outcome. J Neuropathol Exp Neurol 58 : 1061-1068, 1999
 
15) Giannini C, Scheithauer BW, Burger PC et al : Pleomorphic xanthoastrocytoma : what do we really know about it? Cancer 85 : 2033-2045, 1999
PubMed
16) Giannini C, Scheithauer BW, Lopes MB et al : Immunophenotype of pleomorphic xanthoastrocytoma. Am J Surg Pathol 26 : 479-485, 2002
PubMed
17) Ida CM, Vrana JA, Rodriguez FJ et al : Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma. Acta Neuropathol Commun 1 : 20, 2013
PubMed
18) Weber RG, Hoischen A, Ehrler M et al : Frequent loss of chromosome 9, homozygous CDKN2A/p14 (ARF) /CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas. Oncogene 26 : 1088-1097, 2007
PubMed
19) Ida CM, Rodriguez FJ, Burger PC et al : Pleomorphic Xanthoastrocytoma : Natural History and Long-Term Follow-Up. Brain Pathol 25 : 575-586, 2015
PubMed
20) Dias-Santagata D, Lam Q, Vernovsky K et al : BRAF V600E mutations are common in pleomorphic xanthoastrocytoma : diagnostic and therapeutic implications. PLoS One 6 : e17948, 2011
PubMed
21) Yamada S, Kipp BR, Voss JS et al : : Combined "Infiltrating Astrocytoma/Pleomorphic Xanthoastrocytoma" Harboring IDH1 R132H and BRAF V600E Mutations. Am J Surg Pathol 40 : 279-284, 2016
PubMed
22) Hirose T, Ishizawa K, Sugiyama K et al : Pleomorphic xanthoastrocytoma : a comparative pathological study between conventional and anaplastic types. Histopathology 52 : 183-193, 2008
PubMed
P.107 掲載の参考文献
1) McLendon R, Schiffer D, Rosenblum MK et al : Subependymoma. in Louis DN, Ohgaki H, Wiestlers OD et al (eds) : "WHO Classification of Tumours of the Central Nervous System". IARC Press, Lyon, 2016, pp102-103
 
2) McLendon R, Schiffer D, Rosenblum MK et al : Myxopapillary ependymoma. in Louis DN, Ohgaki H, Wiestlers OD et al (eds) : "WHO Classification of Tumours of the Central Nervous System". IARC Press, Lyon, 2016, pp104-105
 
3) Ellison DE, McLendon R, Wiestler OD et al : Ependymoma. in Louis DN, Ohgaki H, Wiestlers OD et al (eds) : "WHO Classification of Tumours of the Central Nervous System". IARC Press, Lyon, 2016, pp106-111
 
4) Witt H, Mack SC, Ryzhova M et al : Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 20 : 143-157, 2011
PubMed
5) Ishizawa K, Komori T, Aihara Y et al : Clear cells are associated with proliferative activity in ependymoma : a quantitative study. Clin Neuropathol 31 : 146-151, 2012
PubMed
6) Ellison DW, Korshunov A, Witt H : Ependymoma, RELA fusion positive. in Louis DN, Ohgaki H, Wiestlers OD et al (eds) : "WHO Classification of Tumours of the Central Nervous System". IARC Press, Lyon, 2016, p112
 
7) Figarella-Branger D, Lechapt-Zalcman E, Tabouret E et al : Supratentorial clear cell ependymomas with branching capillaries demonstrate characteristic clinicopathological features and pathological activation of nuclear factor-kappaB signaling. Neuro Oncol 18 : 919-927, 2016
PubMed
8) Ellison DE, McLendon R, Wiestler OD et al : Anaplastic ependymoma. in Louis DN, Ohgaki H, Wiestlers OD et al (eds) : "WHO Classification of Tumours of the Central Nervous System". IARC Press, Lyon, 2016, pp113-114
 
9) Brat DJ, Fuller GN : Chordoid glioma of the third ventricle. in Louis DN, Ohgaki H, Wiestlers OD et al (eds) : "WHO Classification of Tumours of the Central Nervous System". IARC Press, Lyon, 2016, pp116-118
 
10) Burger, Jouvet A, Preusser M et al : Angiocentric glioma. in Louis DN, Ohgaki H, Wiestlers OD et al (eds) : "WHO Classification of Tumours of the Central Nervous System". IARC Press, Lyon, 2016, pp119-120
 
11) Aldape KD, Rosenblum MK, Brat DJ : Astroblastoma. in Louis DN, Ohgaki H, Wiestlers OD et al (eds) : "WHO Classification of Tumours of the Central Nervous System". IARC Press, Lyon, 2016, pp121-122
 
12) Paulus W, Brandner S, Hawkins C et al : Choroid plexus papilloma. in Louis DN, Ohgaki H, Wiestlers OD et al (eds) : "WHO Classification of Tumours of the Central Nervous System". IARC Press, Lyon, 2016, pp124-126
 
13) Paulus W, Brandner S, Hawkins C et al : Choroid plexus carcinoma. in Louis DN, Ohgaki H, Wiestlers OD et al (eds) : "WHO Classification of Tumours of the Central Nervous System". IARC Press, Lyon, 2016, pp128-129
 
P.120 掲載の参考文献
1) Pietsch T, Hawkins C, Variet R : Dysembryoplastic neuroepithelial tumour. in Louis D, Ohgaki H, Wiestler OD et al (eds) : "WHO Classification of Tumours of the Central Nervous System". IARC Press, Lyon, 2016, pp132-135
 
2) Capper D, Becker A, Glannini C : Gangliocytoma. in Louis D, Ohgaki H, Wiestler OD et a (l eds) : "WHO Classification of Tumours of the Central Nervous System". IARC Press, Lyon, 2016, pp136-137
 
3) Becker A, Wiestler OD, Figarella-Branger D : Ganglioglioma and anaplastic ganglioglioma. in Louis D, Ohgaki H, Wiestler OD et al (eds) : "WHO Classification of Tumours of the Central Nervous System". IARC Press, Lyon, 2016, pp138-141
 
4) Eberhart C, Wiestler OD, Eng C : Dysplastic cerebellar gangliocytoma (Lhermitte-Duclos disease). in Louis D, Ohgaki H, Wiestler OD et al (eds) : "WHO Classification of Tumours of the Central Nervous System". IARC Press, Lyon, 2016, pp142-143
 
5) Brat D, Vanden Berg S, Figarella-Branger D : Desmoplastic infantile astrocytoma and ganglioglioma. in Louis D, Ohgaki H, Wiestler OD et al (eds) : "WHO Classification of Tumours of the Central Nervous System". IARC Press, Lyon, 2016, pp144-146
 
6) Nakazato Y, Figarella-Branger D, Becker A : Papillary glioneuronal tumour. in Louis D, Ohgaki H, Wiestler OD et al (eds) : "WHO Classification of Tumours of the Central Nervous System". IARC Press, Lyon, 2016, pp147-149
 
7) Komori T, Scheithauer BW, Hirose T : A rosette-forming glioneuronal tumor of the fourth ventricle : infratentorial form of dysembryoplastic neuroepithelial tumor? Am J Surg Pathol 26 : 582-591, 2002
 
8) Hainfellner J, Giangaspero F, Rosenblum M : Rosetteforming glioneuronal tumour. in Louis D, Ohgaki H, Wiestler OD et al (eds) : "WHO Classification of Tumours of the Central Nervous System". IARC Press, Lyon, 2016, pp150-151
 
9) Reifenberger G, Rodriguez E, Burger P : Diffuse leptomeningeal glioneuronal tumour. in Louis D, Ohgaki H, Wiestler OD et al (eds) : "WHO Classification of Tumours of the Central Nervous System". IARC Press, Lyon, 2016, pp152-155
 
10) Figarella-Branger D, Soeylemezoglu F, Burger P : Central neurocytoma. in Louis D, Ohgaki H, Wiestler OD et al (eds) : "WHO Classification of Tumours of the Central Nervous System". IARC Press, Lyon, 2016, pp156-158
 
11) Figarella-Branger D, Soeylemezoglu F, Burger P : Extraventricular neurocytoma. in Louis D, Ohgaki H, Wiestler OD et al (eds) : "WHO Classification of Tumours of the Central Nervous System". IARC Press, Lyon, 2016, pp159-160
 
12) Kleihues P, Giangaspero F, Chimelli L : Cerebellar liponeurocytoma. in Louis D, Ohgaki H, Wiestler OD et al (eds) : "WHO Classification of Tumours of the Central Nervous System". IARC Press, Lyon, 2016, pp161-163
 
13) Brandner S, Soffer D, Stratakis C : Paraganglioma. in Louis D, Ohgaki H, Wiestler OD et al (eds) : "WHO Classification of Tumours of the Central Nervous System". IARC Press, Lyon, 2016, pp164-167
 
P.127 掲載の参考文献
1) Hirato J, Nakazato Y : Pathology of pineal region tumors. J Neurooncol 54 : 239-249, 2001
PubMed
2) Louis DN, Ohgaki H, Wiestler OD et al : The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114 : 97-109, 2007
PubMed
3) Hasselblatt M, Jozwiak J, Mayer K et al : Hypothalamic papillary tumor in a patient with tuberous sclerosis. Am J Surg Pathol 32 : 1578-1580, 2008
 
4) Kanno H, Nishihara H, Oikawa M et al : Expression of O6-methylguanine DNA methyltransferase (MGMT) and immunohistochemical analysis of 12 pineal parenchymal tumors. Neuropathology 32 : 647-653, 2012
PubMed
5) Michielsen G, Benoit Y, Baert E et al : Symptomatic pineal cysts : clinical manifestations and management. Acta Neurochir (Wien) 144 : 233-242, 2002
PubMed
6) Fevre-Montange M, Champier J, Szathmari A et al : Microarray analysis reveals differential gene expression patterns in tumors of the pineal region. J Neuropathol Exp Neurol 65 : 675-684, 2006
PubMed
7) Mena H, Armonda RA, Ribas JL et al : Nonneoplastic pineal cysts : a clinicopathologic study of twenty-one cases. Ann Diagn Pathol 1 : 11-18, 1997
PubMed
8) Fauchon F, Jouvet A, Paquis P et al : Parenchymal pineal tumors : a clinicopathological study of 76 cases. Int J Radiat Oncol Biol Phys 46 : 959-968, 2000
PubMed
9) Balossier A, Blond S, Touzet G et al : Role of radiosurgery in the management of pineal region tumours : indications, method, outcome. Neurochirurgie 61 : 216-222, 2015
PubMed
10) Jouvet A, Saint-Pierre G, Fauchon F et al : Pineal parenchymal tumors : a correlation of histological features with prognosis in 66 cases. Brain Pathol 10 : 49-60, 2000
PubMed
11) Fevre-Montange M, Vasiljevic A, Frappaz D et al : Utility of Ki67 immunostaining in the grading of pineal parenchymal tumours : a multicentre study. Neuropathol Appl Neurobiol 38 : 87-94, 2012
PubMed
12) Reis F, Faria AV, Zanardi VA et al : Neuroimaging in pineal tumors. J Neuroimaging 16 : 52-58, 2006
PubMed
13) Nomura K : Epidemiology of germ cell tumors in Asia of pineal region tumor. J Neurooncol 54 : 211-217, 2001
PubMed
14) Fevre-Montange M, Jouvet A, Privat K et al : Immunohistochemical, ultrastructural, biochemical and in vitro studies of a pineocytoma. Acta Neuropathol 95 : 532-539, 1998
PubMed
15) Inda MM, Perot C, Guillaud-Bataille M et al : Genetic heterogeneity in supratentorial and infratentorial primitive neuroectodermal tumours of the central nervous system. Histopathology 47 : 631-637, 2005
PubMed
16) Fevre Montange M, Vasiljevic A, Bergemer Fouquet AM et al : Histopathologic and ultrastructural features and claudin expression in papillary tumors of the pineal region : a multicenter analysis. Am J Surg Pathol 36 : 916-928, 2012
PubMed
17) Dahiya S, Perry A : Pineal tumors. Adv Anat Pathol 17 : 419-427, 2010
PubMed
18) Hasselblatt M, Blumcke I, Jeibmann A et al : Immunohistochemical profile and chromosomal imbalances in papillary tumours of the pineal region. Neuropathol Appl Neurobiol 32 : 278-283, 2006
PubMed
19) Fevre-Montange M, Hasselblatt M, Figarella-Branger D et al : Prognosis and histopathologic features in papillary tumors of the pineal region : a retrospective multicenter study of 31 cases. J Neuropathol Exp Neurol 65 : 1004-1011, 2006
 
P.142 掲載の参考文献
1) Ellison DW, Eberhart CG, Pietsch T et al : Medulloblastoma. in Louis DN, Ohgaki H, Wiestler OD et al (eds) : "WHO Classification of Tumours of the Central Nervous System", 4th ed revised, IARC Press, Lyon, 2016, pp184-188
 
2) Taylor MD, Northcott PA, Korshunov A et al : Molecular subgroups of medulloblastoma : the current consensus. Acta Neuropathol 123 : 465-472, 2012
PubMed
3) Kool M, Korshunov A, Remke M et al : Molecular subgroups of medulloblastoma : an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol 123 : 473-484, 2012
PubMed
4) Hovestadt V, Remke M, Kool M et al : Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. Acta Neuropathol 125 : 913-916, 2013
PubMed
5) Goschzik T, Zur Muhlen A, Kristiansen G et al : Molecular stratification of medulloblastoma : comparison of histological and genetic methods to detect Wnt activated tumours. Neuropathol Appl Neurobiol 41 : 135-144, 2015
PubMed
6) Kaur K, Kakkar A, Kumar A et al : Integrating molecular subclassification of medulloblastomas into routine clinical practice : a simplified approach. Brain Pathol 26 : 334-343, 2016
 
7) Korshunov A, Sturm D, Ryzhova M et al : Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. Acta Neuropathol 128 : 279-289, 2014
PubMed
8) Kleinman CL, Gerges N, Papillon-Cavanagh S et al : Fusion of TTYH1 with the C19MC microRNA cluster drives expression of a brain-specific DNMT3B isoform in the embryonal brain tumor ETMR. Nat Genet 46 : 39-44, 2014
PubMed
9) Spence T, Sin-Chan P, Picard D et al : CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. Acta Neuropathol 128 : 291-303, 2014
 
10) Nobusawa S, Orimo K, Horiguchi K et al : Embryonal tumor with abundant neuropil and true rosettes with only one structure suggestive of an ependymoblastic rosette. Pathol Int 64 : 472-477, 2014
PubMed
11) Korshunov A, Ryzhova M, Jones DT et al : LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR). Acta Neuropathol 124 : 875-881, 2012
PubMed
12) Nobusawa S, Yokoo H, Hirato J et al : Analysis of chromosome 19q13.42 amplification in embryonal brain tumors with ependymoblastic multilayered rosettes. Brain Pathol 22 : 689-697, 2012
PubMed
13) Nobusawa S, Suzuki A, Nagaishi M et al : Anaplastic ependymoma with ependymoblastic multilayered rosettes. Hum Pathol 44 : 2597-2602, 2013
PubMed
14) Schrey D, Carceller Lechon F, Malietzis G et al : Multimodal therapy in children and adolescents with newly diagnosed atypical teratoid rhabdoid tumor : individual pooled data analysis and review of the literature. J Neurooncol 126 : 81-90, 2016
PubMed
15) Fischer-Valuck BW, Chen I, Srivastava AJ et al : Assessment of the treatment approach and survival outcomes in a modern cohort of patients with atypical teratoid rhabdoid tumors using the National Cancer Database. Cancer 123 : 682-687, 2017
 
16) Rorke LB, Packer RJ, Biegel JA : Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood : definition of an entity. J Neurosurg 85 : 56-65, 1996
PubMed
17) Deisch J, Raisanen J, Rakheja D : Immunohistochemical expression of embryonic stem cell markers in malignant rhabdoid tumors. Pediatr Dev Pathol 14 : 353-359, 2011
PubMed
18) Judkins AR, Burger PC, Hamilton RL et al : INI1 protein expression distinguishes atypical teratoid/rhabdoid tumor from choroid plexus carcinoma. J Neuropathol Exp Neurol 64 : 391-397, 2005
PubMed
19) Paulus W, Brandner S, Hawkins C et al : Choroid plexus carcinoma. in Luis DN, Ohgaki H, Wiestler OD et al (eds) : "WHO Classification of Tumours of the Central Nervous System", 4th ed revised, IARC Press, Lyon, 2016, pp128-129
 
P.153 掲載の参考文献
1) Perry A, Louis DN, Budka H et al : Meningioma. in Louis DN, Ohgaki H, Wiestler OD et al (eds) : "WHO Classification of Tumours of the Central Nervous System", 4th edition revised, IARC Press, Lyon, 2016, pp232-233
 
2) Louis DN, Perry A, Reifenberger G et al : The 2016 World Health Organization Classification of Tumors of the Central Nervous System : a summary. Acta Neuropathol 131 : 803-820, 2016
PubMed
3) Perry A, Louis DN, Budka H et al : Meningioma. in Louis DN, Ohgaki H, Wiestler OD et al (eds) : "WHO Classification of Tumours of the Central Nervous System", 4th edition revised, IARC Press, Lyon, 2016, pp237-240
 
4) Menke JR, Raleigh DR, Gown AM et al : Somatostatin receptor 2a is a more sensitive diagnostic marker of meningioma than epithelial membrane antigen. Acta Neuropathol 130 : 441-443, 2015
PubMed
5) 安倍雅人 : 血管腫性髄膜腫, 病理診断クイックリファレンス. 病理と臨床 33 (臨増) : 331, 2015
 
6) Paek SH, Kim SH, Chang KH et al : Microcystic meningiomas : radiological characteristics of 16 cases. Acta Neurochir (Wien) 147 : 965-972, 2005
PubMed
7) 日本脳神経外科学会, 日本病理学会 (編) : 臨床・病理 脳腫瘍取扱い規約 臨床と病理カラーアトラス, 第3版. 金原出版, 2010, p137
 
8) Tirakotai W, Mennel HD, Celik I et al : Secretory meningioma : immunohistochemical findings and evaluation of mast cell infiltration. Neurosurg Rev 29 : 41-48, 2006
PubMed
9) 安倍雅人, 中里洋一 : 特異な組織像と症候を示す髄膜腫. Clinical Neuroscience 18 : 12-13, 2000
 
10) 安倍雅人, 黒田誠 : Lymphoplasmacyte-rich meningiomaリンパ球・形質細胞に富む髄膜腫. 日本脳腫瘍病理学会 (編) : 脳腫瘍臨床病理カラーアトラス, 第3版. 医学書院, 2009, p112
 
11) 安倍雅人 : 炎症性髄膜腫瘤. 病理形態学キーワード. 病理と臨床 28 (臨増) : 432-433, 2010
 
12) Perry A, Louis DN, Budka H et al : Meningioma. in Louis DN, Ohgaki H, Wiestler OD et al (eds) : WHO Classification of Tumours of the Central Nervous System, 4th edition revised, IARC Press, Lyon, 2016, pp240-242
 
13) Kepes JJ, Chen WY, Connors MH et al : "Chordoid" meningeal tumors in young individuals with peritumoral lymphoplasmacellular infiltrates causing systemic manifestations of the Castleman syndrome. A report of seven cases. Cancer 62 : 391-406, 1988
PubMed
14) 吉田朗彦 : 髄膜腫. 脳腫瘍学. 日本臨牀 74 (増刊 7) : 222-224, 2016
 
15) Perry A, Louis DN, Budka H et al : Meningioma. in Louis DN, Ohgaki H, Wiestler OD et al (eds) : WHO Classification of Tumours of the Central Nervous System, 4th edition revised, IARC Press, Lyon, 2016, pp242-245
 
16) Wu YT, Ho JT, Lin YJ et al : Rhabdoid papillary meningioma : a clinicopathologic case series study. Neuropathology 31 : 599-605, 2011
PubMed
17) Vaubel RA, Chen SG, Raleigh DR et al : Meningiomas with rhabdoid features lacking other histologic features of malignancy : a study of 44 cases and review of the literature. J Neuropathol Exp Neurol 75 : 44-52, 2016
PubMed
P.159 掲載の参考文献
1) Pekmezci M, Reuss DE, Hirbe AC et al : Morphologic and immunohistochemical features of malignant peripheral ner ve sheath tumors and cellular schwannomas. Mod Pathol 28 : 187-200, 2015
 
2) Scheitauer BW, Woodruff JM, Erlandson RA : Atlas of Tumor Pathology, 3rd series, fascicle 24, Tumors of the Peripheral Nervous System. Armed Forces Institute of Pathology, Washington D.C, 1999, pp202-213, 308-314
 
3) Goldblum JR, FolpeAL, Weiss SW : Enzinger and Weiss's Soft Tissue Tumors, 6th ed, Mosby, Edinburgh, 2014, pp812-813
 
4) Perry A, von Deimling A, Louis DN et al : Neurofibroma. in Louis DN, Ohgaki H, Wiestler OD et al (eds) : "WHO Classification of Tumours of the Central Nervous System". IARC Press, Lyon, 2016, p220
 
5) L'heureux-Lebeau B, Saliba I : Updates on the diagnosis and treatment of intracranial nerve malignant peripheral ner ve sheath tumors. Onco Targets Ther 6 : 459-470, 2013
 
6) Rodriguez FJ, Folpe AL, Giannini C et al : Pathology of peripheral nerve sheath tumors : diagnostic overview and update on selected diagnostic problems. Acta Neuropathol 123 : 295-319, 2012
PubMed
7) Schaefer IM, Fletcher CD, Hornick JL : Loss of H3K27 trimethylation distinguishes malignant peripheral ner ve sheath tumors from histologic mimics. Mod Pathol 29 : 4-13, 2016
 
8) Rohrich M, Koelsche C, Schrimpf D et al : Methylationbased classification of benign and malignant peripheral nerve sheath tumors. Acta Neuropathol 131 : 877-887, 2016
PubMed
9) Cleven AH, Sannaa GA, Briaire-de Bruijn I et al : Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. Mod Pathol 29 : 582-590, 2016
 
P.166 掲載の参考文献
1) Louis DN, Ohgaki H, Wiestler OD et al (eds) : WHO Classification of Tumours of the Central Nervous System, IARC Press, Lyon, 2016
 
2) Fletcher CDM, Bridge JA, Hogendoorn PCW et al (eds) : WHO Classification of Tumours of Soft Tissue and Bone, IARC Press, Lyon, 2013
 
3) Perry A, Scheithauer BW, Nascimento AG : The immunophenotypic spectrum of meningeal hemangiopericytoma : a comparison with fibrous meningioma and solitary fibrous tumor of meninges. Am J Surg Pathol 21 : 1354-1360, 1997
PubMed
4) Suzuki SO, Fukui M, Nishio S et al : Clinicopathological features of solitary fibrous tumor of the meninges : An immunohistochemical reappraisal of cases previously diagnosed to be fibrous meningioma or hemangiopericytoma. Pathol Int 50 : 808-817, 2000
PubMed
5) Robinson DR, Wu YM, Kalyana-Sundaram S et al : Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet 45 : 180-185, 2013
PubMed
6) Yoshida A, Tsuta K, Ohno M et al : STAT6 immunohistochemistry is helpful in the diagnosis of solitary fibrous tumors. Am J Surg Pathol 38 : 552-559, 2014
PubMed
7) Cheah AL, Billings SD, Goldblum JR et al : STAT6 rabbit monoclonal antibody is a robust diagnostic tool for the distinction of solitary fibrous tumour from its mimics. Pathology 46 : 389-395, 2014
PubMed
8) Polydorides AD, Rosenblum MK, Edgar MA : Metastatic renal cell carcinoma to hemangioblastoma in von Hippel-Lindau disease. Arch Pathol Lab Med 131 : 641-645, 2007
PubMed
9) Oakley GJ, Fuhrer K, Seethala RR : Brachyury, SOX-9, and podoplanin, new markers in the skull base chordoma vs chondrosarcoma differential : a tissue microarray-based comparative analysis. Mod Pathol 21 : 1461-1469, 2008
PubMed
10) Sturm D, Orr BA, Toprak UH et al : New brain tumor entities emerge from molecular classification of CNS-PNETs. Cell 164 : 1060-1072, 2016
PubMed
11) Joseph NM, Phillips J, Dahiya S et al : Diagnostic implications of IDH1-R132H and OLIG2 expression patterns in rare and challenging glioblastoma variants. Mod Pathol 26 : 315-326, 2013
PubMed
P.177 掲載の参考文献
1) Deckert M, Paulus W : Lymphomas. in Louis DN, Ohgaki H, Wiestler OD et al (eds) : "WHO Classification of Tumours of the Central Nervous System". IARC Press, Lyon, 2016, pp272-277
 
2) Sugita Y : Pathology of primary central nervous system lymphomas. in Yamanaka R (ed) : "Primary Central Nervous System Lymphomas, Incidence, Management, and Outcomes". Nova Science Publishers, New York, 2016, pp9-22
 
3) Giannini C, Dogan A, Salomao DR : CNS lymphoma : a practical diagnostic approach. J Neuropathol Exp Neurol 73 : 478-494, 2014
PubMed
4) Krieken JHV, Swerdlow SH, Jaffe ES et al : Immunodeficiency-associated lymphoproliferative disorders. in Swerdlow SH, Campo E, Harris NL et al (eds) : "WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues". IARC Press, Lyon, 2007, pp335-351
 
5) Menon MP, Nicolae A, Meeker H et al : Primary CNS T cell lymphomas : a clinical, morphologic, immunophenotypic, and molecular analysis. Am J Surg Pathol 39 : 1719-1729, 2015
PubMed
6) Guan H, Huang Y, Wen W et al : Primary central nervous system extranodal NK/T-cell lymphoma, nasal type : case report and review of the literature. J Neurooncol 103 : 387-391, 2011
 
7) 大島孝一, 木村芳三 : 未分化大細胞型リンパ腫-ALK陽性. 中村栄男, 飯田真介, 大島孝一 他 (編) : WHO血液腫瘍分類. 医薬ジャーナル社, 2010, pp502-507
 
8) Nomura M, Narita Y, Miyakita Y et al : Clinical presentation of anaplastic large-cell lymphoma in the central nervous system. Mol Clin Oncol 1 : 655-660, 2013
PubMed
9) Pittaluga S, Wilson WH, Jaffe ES : Lymphomatoid granulomatosis. in Swerdlow SH, Campo E, Harris NL et al (eds) : "WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues". IARC Press, Lyon, 2007, pp247-249
 
10) Tu PH, Giannini C, Judkins AR et al : Clinicopathologic and genetic profile of intracranial marginal zone lymphoma : a primary low-grade CNS lymphoma that mimics meningioma. J Clin Oncol 23 : 5718-5727, 2005
PubMed
11) Hervier B, Haroche J, Arnaud L et al : Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. Blood 124 : 1119-1126, 2014
 
12) Tian Y, Wang J, Li M et al : Rosai-Dorfman disease involving the central nervous system : seven cases from one institute. Acta Neurochir (Wien) 157 : 1565-1571, 2015
 
13) 大島孝一 : 播種性若年性黄色肉芽腫症. 中村栄男, 飯田真介, 大島孝一他 (編) : WHO 血液腫瘍分類. 医薬ジャーナル社, 2010, pp575-576
 
14) Chen CJ, Williams EA, McAneney TE et al : Histiocytic sarcoma of the cavernous sinus : case report and literature review. Brain Tumor Pathol 32 : 66-71, 2015
PubMed
15) 大島孝一, 喜安純一 : 組織球性肉腫. 中村栄男, 飯田真介, 大島孝一 他 (編) : WHO血液腫瘍分類. 医薬ジャーナル社, 2010, pp554-557
 
P.183 掲載の参考文献
1) Rosenblum MK, Ichimura K, Nakazato Y et al : Germ cell tumours. in Louis DN, Ohgaki H, Wiestlers OD et al (eds) : "WHO Classification of Tumours of the Central Nervous System, 4th ed revised". IARC Press, Lyon, 2016, pp285-291
 
2) Hattab EM : Germ cell tumors. in Perry A, Brat DJ (eds) : "Practical Surgical Neuropathology. A diagnostic Approach". Churchill Livingstone, Philadelphia, 2010, pp333-351
 
3) 佐々木惇 : 松果体部腫瘍の病理診断. Neuro-Oncologyの進歩 18 : 1-8, 2013
 

第3部 鑑別ポイント

P.192 掲載の参考文献
1) Joseph JT : Diagnostic Neuropathology Smears. Lippincott Williams & Wilkins, Philadelphia, 2007
 
2) Burger PC : Smears and Frozen Sections in Surgical Neuropathology. PB Medical Publishing, Baltimore, 2009
 
3) Fuller GN : Intraoperative consultation and optimal processing. in Perry A, Brat DJ (eds) : "Practical Surgical Neuropathology". Churchill Livingstone, Philadelphia, 2009, pp35-45
 
4) 日本臨床細胞学会 (編) : 中枢神経/脳脊髄液. 細胞診ガイドライン 3, 金原出版, 2015, pp130-179
 
5) Brainard JA, Prayson RA, Barnett GH : Frozen section evaluation of stereotactic brain biopsies : diagnostic yield at the stereotactic target position in 188 cases. Arch Pathol Lab Med 121 : 481-484, 1997
PubMed
6) Raisanen J, White CL III : Central nervous system. in Taxy JB, Husain AN, Montag AG (eds) : "Biopsy Interpretation : The Frozen Section". Lippincott Williams & Wilkins, Philadelphia, 2010, pp303-338
 
7) 土居美枝子, 金野美年子, 瀬山幸子他 : 脳原発悪性リンパ腫診断におけるlymphoglandular body有用性の検討. 日臨細胞会誌 51 (Suppl 1) : 426, 2012
 
P.201 掲載の参考文献
1) Louis DN, Ohgaki H, Wiestler OD et al (eds) : WHO Classification of Tumours of the Central Nervous System, 4th ed revised. IARC Press, Lyon, 2016
 
2) Capper D, Zentgraf H, Balss J et al : Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 118 : 599-601, 2009
PubMed
3) Arita H, Narita Y, Yoshida A et al : IDH1/2 mutation detection in gliomas. Brain Tumor Pathol 32 : 79-89, 2015
PubMed
4) Ikemura M, Shibahara J, Mukasa A et al : Utility of ATRX immunohistochemistry in diagnosis of adult diffuse gliomas. Histopathology 69 : 260-267, 2016
PubMed
5) Takami H, Yoshida A, Fukushima S et al : Revisiting TP53 mutations and immunohistochemistry. A comparative study in 157 diffuse gliomas. Brain Pathol 25 : 256-265, 2015
PubMed
6) Colman H, Giannini C, Huang L et al : Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediategrade infiltrating astrocytomas. Am J Surg Pathol 30 : 657-664, 2006
PubMed
7) Preusser M, Charles Janzer R, Felsberg J et al : Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme : observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol 18 : 520-532, 2008
PubMed
8) Peraud A, Watanabe K, Plate KH et al : p53 mutation versus EGF receptor expression in giant cell glioblastomas. J Neuropathol Exp Neurol 56 : 1236-1241, 1997
PubMed
9) Kleinschmidt-DeMasters BK, Aisner DL, Foreman NK : BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation. Am J Surg Pathol 39 : 528-540, 2015
PubMed
10) Kleinschmidt-DeMasters BK, Alassiri AH, Birks DK et al : Epithelioid versus rhabdoid glioblastomas are distinguished by monosomy 22 and immunohistochemical expression of INI-1 but not claudin 6. Am J Surg Pathol 34 : 341-354, 2010
 
11) Hirose T, Ishizawa K, Shimada S : Utility of in situ demonstration of 1p loss and p53 overexpression in pathologic diagnosis of oligodendroglial tumors. Neuropathology 30 : 586-596, 2010
PubMed
12) Eigenbrod S, Roeber S, Thon N et al : α-internexin in the diagnosis of oligodendroglial tumors and association with 1p/19q status. J Neuropathol Exp Neurol 70 : 970-978, 2011
 
13) Ishizawa K, Komori T, Shimada S et al : Podoplanin is a potential marker for the diagnosis of ependymoma : a comparative study with epithelial membrane antigen (EMA). Clin Neuropathol 28 : 373-378, 2009
PubMed
14) Ishizawa K, Komori T, Shimada S et al : Olig2 and CD99 are useful negative markers for the diagnosis of brain tumors. Clin Neuropathol 27 : 118-128, 2008
PubMed
15) Parker M, Mohankumar KM, Punchihewa C et al : C11orf95-RELA fusions drive oncogenic NF-κB signaling in ependymoma. Nature 506 : 451-455, 2014
 
16) Koelsche C, Wohrer A, Jeibmann A et al : Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. Acta Neuropathol 125 : 891-900, 2013
PubMed
17) Ellison DW, Dalton J, Kocak M et al : Medulloblastoma : clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol 121 : 381-396, 2011
PubMed
18) Korshunov A, Ryzhova M, Jones DT et al : LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR). Acta Neuropathol 124 : 875-881, 2012
PubMed
19) Menke JR, Raleigh DR, Gown AM et al : Somatostatin receptor 2a is a more sensitive diagnostic marker of meningioma than epithelial membrane antigen. Acta Neuropathol 130 : 441-443, 2015
PubMed
20) Schweizer L, Koelsche C, Sahm F et al : Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol 125 : 651-658, 2013
PubMed
P.209 掲載の参考文献
1) Cunliffe CH, Fischer I, Monoky D et al : Intracranial lesions mimicking neoplasms. Arch Pathol Lab Med 133 : 101-123, 2009
PubMed
2) Rivera-Zengotita M, Yachnis AT : Gliosis versus glioma? : don't grade until you know. Adv Anat Pathol 19 : 239-249, 2012
 
3) Suzuki SO, Kitai R, Llena J et al : MAP-2e, a novel MAP-2 isoform, is expressed in gliomas and delineates tumor architecture and patterns of infiltration. J Neuropathol Exp Neurol 61 : 403-412, 2002
PubMed
4) Kitai R, Horita R, Sato K et al : Nestin expression in astrocytic tumors delineates tumor infiltration. Brain Tumor Pathol 27 : 17-21, 2010
PubMed
5) Masui K, Mawatari SY, Suzuki SO et al : Evaluation of sensitivity and specificity of doublecortin immunostatining for the detection of infiltrating glioma cells. Brain Tumor Pathol 25 : 1-7, 2008
PubMed
6) Alderson L, Fetell MR, Sisti M et al : Sentinel lesions of primary CNS lymphoma. J Neurol Neurosurg Psychiatry 60 : 102-105, 1996
PubMed
7) Brandsma D, Stalpers L, Taal W et al : Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9 : 453-461, 2008
PubMed
8) Mullins ME, Barest GD, Schaefer PW et al : Radiation necrosis versus glioma recurrence : conventional MR imaging clues to diagnosis. AJNR Am J Neuroradiol 26 : 1967-1972, 2005
PubMed
9) Brouwer MC, Coutinho JM, van de Beek D : Clinical characteristics and outcome of brain abscess : systematic review and meta-analysis. Neurology 82 : 806-813, 2014
PubMed
10) Smith AB, Smirniotopoulos JG, Rushing EJ : From the archives of the AFIP : central nervous system infections associated with human immunodeficiency virus infection : radiologic-pathologic correlation. Radiographics 28 : 2033-2058, 2008
PubMed
11) Bowen LN, Smith B, Reich D et al : HIV-associated opportunistic CNS infections : pathophysiology, diagnosis and treatment. Nat Rev Neurol 12 : 662-674, 2016
PubMed
12) Bradley D, Rees J : Brain tumour mimics and chameleons. Pract Neurol 13 : 359-371, 2013
PubMed
13) Okamoto K, Furusawa T, Ishikawa K et al : Mimics of brain tumor on neuroimaging : part I. Radiat Med 22 : 63-76, 2004
PubMed
14) 鈴木諭 : 進行性多巣性白質脳症Progressive multifocal leukoencephalopathy (PML). 病理診断クイックリファレンス, 病理と臨床 33 (臨増) : 335, 2015
 
15) Lucchinetti CF, Gavrilova RH, Metz I et al : Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 131 : 1759-1775, 2008
PubMed
16) Tenembaum S, Chitnis T, Ness J et al : Acute disseminated encephalomyelitis. Neurology 68 (16 Suppl 2) : S23-S36, 2007
 
17) Anderson MD, Colen RR, Tremont-Lukats IW : Imaging mimics of primary malignant tumors of the central nervous system (CNS). Curr Oncol Rep 16 : 399, 2014
 
18) Shinoda K, Asahara H, Uehara T et al : Multiphasic acute disseminated encephalomyelitis associated with atypical rubella virus infection. Mult Scler 21 : 252-254, 2015
PubMed
19) Jennette JC, Falk RJ, Bacon PA et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013
 
20) 水野裕, 重藤寛, 山田猛 他 : 2回目の脳生検により原発性中枢神経系血管炎の確定診断に至り治療しえた1例, 臨床神経 56 : 186-190, 2016
 
21) Coutinho JM : Cerebral venous thrombosis. J Thromb Haemost 13 (Suppl 1) : S238-S244, 2015
 

第4部 臨床との連携

P.216 掲載の参考文献
1) 全国がん (成人病) センター協議会 : 全がん協, 部位別臨床期別, 10年相対生存率 (2000-2003年診断症例) http://www.zengankyo.ncc.go.jp/etc/2000-2003_10all.html
 
2) 岡田知久, 三木幸雄 : MRI. 川原信隆, 野崎和彦, 吉峰俊彦 他 (編) : 脳神経外科学, 改訂12版. 金芳堂, 2016, pp388-412
 
3) Westphal M, Hilt DC, Bortey E et al : A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5 : 79-88, 2003
 
4) Aoki T, Nishikawa R, Sugiyama K et al : A multicenter phase I/II study of the BCNU implant (GliadelR Wafer) for Japanese patients with malignant gliomas. Neurol Med Chir (Tokyo) 54 : 290-301, 2014
 
5) Gerlinger M, Rowan AJ, Horswell S et al : Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366 : 883-892, 2012
PubMed
6) Suzuki H, Aoki K, Chiba K et al : Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 47 : 458-468, 2015
PubMed
7) Skoulidis F, Papadimitrakopoulou VA : Targeting the gatekeeper : osimertinib in EGFR T790M mutation-positive non-small cell lung cancer. Clin Cancer Res 23 : 618-622, 2017
PubMed
8) Stupp R, Mason WP, van den Bent MJ et al : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 : 987-996, 2005
PubMed
9) Wakabayashi T, Natsume A, Mizusawa J et al : JCOG0911 Integra Trial : A randomized screening phase II trial of chemoradiotherapy with interferonβ plus temozolomide versus chemoradiotherapy with temozolomide alone for newly-diagnosed glioblastoma. Neuro Oncol 2014, 16 (suppl 5) : v21, https://doi.org/10.1093/neuonc/nou237.57
 
10) Kumabe T, Sato K, Iwasaki M et al : Summary of 15 years experience of awake surgeries for neuroepithelial tumors in Tohoku university. Neurol Med Chir (Tokyo) 53 : 455-466, 2013
PubMed
11) 谷口浩也 : 大腸がん, 肛門がん. 日本臨床腫瘍学会 (編) : 新臨床腫瘍学, 改訂第4版. 南江堂, 2015, pp386-395
 
12) Paszat L, Laperriere N, Groome P et al : A populationbased study of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 51 : 100-107, 2001
 
13) Keime-Guibert F, Chinot O, Taillandier L et al : Radiotherapy for glioblastoma in the elderly. N Engl J Med 356 : 1527-1535, 2007
PubMed
14) Roa W, Brasher PM, Bauman G et al : Abbreviated course of radiation therapy in older patients with glioblastoma multiforme : a prospective randomized clinical trial. J Clin Oncol 22 : 1583-1588, 2004
PubMed
15) Malmstrom A, Gronberg BH, Marosi C et al : Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma : the Nordic randomised, phase 3 trial. Lancet Oncol 13 : 916-926, 2012
PubMed
16) Wick W, Platten M, Meisner C et al : Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly : the NOA-08 randomised, phase 3 trial. Lancet Oncol 13 : 707-715, 2012
PubMed
17) Brandes AA, Vastola F, Basso U et al : A prospective study on glioblastoma in the elderly. Cancer 97 : 657-662, 2003
PubMed
18) Perry JR, Laperriere N, O'Callaghan CJ et al : Shortcourse radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med 376 : 1027-1037, 2017
PubMed
19) Laperriere N, Weller M, Stupp R et al : Optimal management of elderly patients with glioblastoma. Cancer Treat Rev 39 : 350-357, 2013
PubMed
20) 日本脳腫瘍学会 (編) : 中枢神経系原発悪性リンパ腫. 脳腫瘍診療ガイドライン. 金原出版, 2016, pp97-128
 
P.223 掲載の参考文献
1) 平井俊範 : グリオーマの再発, 放射線壊死, 偽増悪, 偽奏効の鑑別診断. 橋本信夫 (監), 三國信啓 (編) : 脳神経外科診療プラクティス グリオーマ治療のDecision Making. 文光堂, 2016, pp28-31
 
2) Petrecca K, Guiot M-C, Panet-Raymond V et al : Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma. J Neurooncol 111 : 19-23, 2013
 
3) 西川亮 : ジャーミノーマ. 神経症候群 (第2版) (III) -その他の神経疾患を含めて-. 別冊 日本臨牀 日本臨新領域別症候群シリーズ No.28. 日本臨牀社, 2014, pp347-351
 
4) 三島一彦 : 中枢神経系原発悪性リンパ腫. 神経症候群 (第2版) (III) -その他の神経疾患を含めて-. 別冊 日本臨牀 日本臨新領域別症候群シリーズ No.28. 日本臨牀社, 2014, pp323-331
 
5) 溝脇尚志 : 放射線療法. 橋本信夫 (監), 三國信啓 (編) : 脳神経外科診療プラクティス グリオーマ治療のDecision Making. 文光堂, 2016, pp233-235
 
6) Sheline GE : Radiation therapy of brain tumors. Cancer 39 : 873-881, 1977
PubMed
7) Fink J, Born D, Chamberlain MC : Radiation Necrosis : Relevance with respect to treatment of primary and secondary brain tumor. Curr Neurol Neurosci Rep 12 : 276-285, 2012
PubMed
8) Perry A, Schmidt RE : Cancer therapy-associated CNS neuropathology : an update and review of the literature. Acta Neuropathol 111 : 197-212, 2006
PubMed
9) Perry A : Therapy-associated neuropathology. in Perry A, Brat DJ (eds) : "Practical Ssurgical Neuropathology : A Diagnostic Approach". Churchill Livingstone, Philadelphia, 2010, pp417-425
 
10) Schultheiss TE, Kun LE, Ang KK et al : Radiation response of the central nervous system. Int J Radiation Oncology Biol Phys 31 : 1093-1112, 1995
 
11) Martins AN, Johnston JS, Henry MH et al : Delayed radiation necrosis of the brain. J Neurosurg 47 : 336-345, 1977
 
12) Forsyth PA, Kelly PJ, Cascino TL et al : Radiation necrosis or glioma recurrence : is computer-assisted stereotactic biopsy useful? J Neurosurg 82 : 436-444, 1995
PubMed
P.229 掲載の参考文献
1) Louis DN, Perry A, Burger P et al : International Society of Neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 24 : 429-435, 2014
PubMed
2) Louis DN, Ohgaki H, Wiestler OD et al (eds) : Diffuse astrocytic and oligodendroglial tumours. in "WHO Classification of Tumours of the Central Nervous System", IARC Press, Lyon, 2016
 

書評

最近チェックした商品履歴

Loading...